HC Wainwright Issues Positive Forecast for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Research analysts at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for Harrow in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.65 per share for the quarter, up from their previous forecast of $0.61. The consensus estimate for Harrow’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Harrow’s Q3 2027 earnings at $0.32 EPS.

Other equities analysts have also recently issued research reports about the stock. Zacks Research cut shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. BTIG Research reiterated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday. Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Finally, Leerink Partners started coverage on shares of Harrow in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $66.20.

Harrow Price Performance

NASDAQ HROW opened at $29.37 on Thursday. Harrow has a one year low of $25.76 and a one year high of $54.85. The stock has a 50-day moving average of $31.15 and a 200 day moving average of $37.67. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -37.65 and a beta of 0.18. The company has a debt-to-equity ratio of 10.15, a quick ratio of 2.08 and a current ratio of 2.29.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The firm had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new stake in shares of Harrow during the 2nd quarter valued at about $4,565,000. FirstWave Capital Management LLC increased its position in shares of Harrow by 47.3% during the 2nd quarter. FirstWave Capital Management LLC now owns 211,981 shares of the company’s stock valued at $9,003,000 after purchasing an additional 68,058 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after purchasing an additional 208,972 shares during the last quarter. Luxor Capital Group LP lifted its stake in shares of Harrow by 22.0% in the 1st quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock worth $39,470,000 after purchasing an additional 201,859 shares during the period. Finally, Rice Hall James & Associates LLC bought a new position in shares of Harrow in the 2nd quarter worth approximately $16,459,000. Institutional investors own 72.76% of the company’s stock.

Insider Activity

In related news, insider Amir Shojaei sold 11,250 shares of Harrow stock in a transaction on Friday, August 14th. The stock was sold at an average price of $40.00, for a total value of $450,000.00. Following the completion of the sale, the insider owned 11,250 shares of the company’s stock, valued at $450,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 12.80% of the stock is currently owned by company insiders.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.